Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21047720 | 0.89 | GRIN2D (0.65) | PLD1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29857922 | 0.83 | PLD1 (0.73) | PLD1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21353591 | 0.83 | — | — | |
| SCHEMBL15800694 | 0.83 | PLD1 (0.73) | PLD1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9200836 | 0.81 | LMNA (0.53) | MAPTLMNA | |
| SCHEMBL157489 | 0.79 | PLD1 (0.68) | PLD1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29462629 | 0.79 | PLD1 (0.68) | PLD1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL230367 | 0.79 | PLD1 (0.68) | PLD1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL18228078 | 0.79 | PLD1 (0.68) | PLD1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21047722 | 0.79 | GRIN2D (0.57) | PLD1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760747-B2 | Substituted piperidino compounds and related methods of treatment | ALKERMES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760747-B2 | Substituted piperidino compounds and related methods of treatment | ALKERMES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| CN-116670124-A | Substituted piperidines and related methods of treatment | 阿尔克姆斯有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022140317-A1 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220194926-A1 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-06-23 | — | — | US | disclosed |
| CN-107108656-B | N- substitution -3,5- disubstituted benzenes Carbox amide and its preparation method and application | 中国科学院上海药物研究所 | 2019-11-05 | — | — | CN | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| EP-1773796-A2 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021655-A2 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | PLD1 4699/4885GRIN2D 4571/4885GRIN3B 4314/4885 |
| US-20220194926-A1 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | HCRTR1, HCRTR2, PNMT | PLD1 372/4885GRIN2D 115/4885GRIN3B 58/4885 |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | MC5R, MC4R, OPRD1 | PLD1 1972/4885GRIN2D 808/4885GRIN3B 481/4885 |
| US-11760747-B2 | Substituted piperidino compounds and related methods of treatment | HCRTR1, HCRTR2, PNMT | PLD1 372/4885GRIN2D 115/4885GRIN3B 58/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | PLD1 2444/4885GRIN2D 2816/4885GRIN3B 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.